SERA Sera Prognostics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why SERA matters now
Sera Prognostics, Inc. (SERA) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.97 with -4.37% on the session and $75.2M in market capitalization; recent performance reads 1-month +0.57% and YTD -40.68%.
The latest financial table shown here is Q1 2026, with revenue of $14.0K, net income of $-8.4M, and EPS of $-0.17. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -41.3%.
The latest indexable market news headline is "PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.00; recent insider activity includes Jackson Benjamin filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.30
P/S
1172.53
EV/EBITDA
-2.09
DCF Value
$-0.02
FCF Yield
-41.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
-191.2%
Operating Margin
-64235.1%
Net Margin
-56386.0%
ROE
-41.0%
ROA
-34.4%
ROIC
-52.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $14.0K | $-8.4M | $-0.17 |
| Q4 2025 | $10.0K | $-7.9M | $-0.16 |
| FY 2025 | $81.0K | $-31.9M | $-0.67 |
| Q3 2025 | $16.0K | $-7.8M | $-0.16 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$6.00
Target (Median)
$6.00
Target Range
$6.00 - $6.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
0.94
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.